Day: March 19, 2024

Figure 1REVEAL Phase 1/2 Adolescent and Adult Trial Data from Cohort OneData from first adult patient in REVEAL Phase 1/2 trial showed TSHA-102 (low dose, 5.7×1014 total vg) was well-tolerated with no treatment-emergent SAEs as of 35-week assessment, with sustained improvement across key efficacy measures at decreased steroid levels and new improvement in RSBQ at month six Data from second adult patient showed TSHA-102 (low dose, 5.7×1014 total vg) was well-tolerated with no treatment-emergent SAEs as of 19-week assessment, with sustained improvement across key efficacy measures, significantly reduced seizure events and new improvement in R-MBA at week 12 Principal Investigator observed sustained and new improvements across multiple clinical domains following completion of steroid taper for patient one through 35-weeks...

Highlights of the fiscal year include:Revenue of $999.6 million, an increase of 16% compared to $861.7 million in FY23. Net income of $55.7 million, compared to net loss of $26.1 million in FY23, with non-GAAP net income of $195.5 million, compared to $114.5 million in FY23. Net income per diluted share of $0.64, compared to net loss per diluted share of $0.31 in FY23, with non-GAAP net income per diluted share of $2.25, compared to $1.36 in FY23. Adjusted EBITDA of $369.2 million, an increase of 36% compared to $272.3 million in FY23. 8.7 million HSAs, an increase of 9% compared to FY23. Total HSA Assets of $25.2 billion, an increase of 14% compared to FY23. 15.7 million Total Accounts, including both HSAs and complementary CDBs, an increase of 5% compared to FY23. The Company agreed to acquire the BenefitWallet HSA portfolio.Highlights...

PRESS RELEASE Online investor presentation and Q&A at 10.30 CET on 20 March 2024 via:https://channel.royalcast.com/cabka/#!/cabka/20240320_12023: Strategy on track, driving improved profitabilitySales of € 197 million (2022: € 209 million) Operational EBITDA 8% higher at € 24.2 million (2022: € 22.5 million) Net Income from operations € 2.5 million (2022: € 1.6 million) Cash flow from operating activities significantly improved to € 27.1 million (2022: € 5.3 million) Recycled raw material inflow at 89% (2022: 86%) Successfully secured debt refinancing of € 80 million at improved terms Proposed cash distribution of € 0.15 per shareAmsterdam 19 March 2024. Cabka N.V. (together with its subsidiaries “Cabka”, or the “Company”), a company specialized in transforming hard to recycle plastic waste into innovative Reusable Transport...

Public release of Virbac Consolidated Accounts at 31 December 2023. The Group released its 2023 Consolidated Accounts. The document is available on the corporate website, at corporate.virbac.com, under “Investors”, “Financial Reports”.AttachmentPublic release of Virbac Consolidated Accounts 12.2023